Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF T599K |
Therapy | Dabrafenib |
Indication/Tumor Type | breast cancer |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF T599K | breast cancer | predicted - resistant | Dabrafenib | Preclinical | Actionable | In a preclinical study, Tafinlar (dabrafenib) treatment did not inhibit Erk phosphorylation in breast cancer cells expressing BRAF T599K in culture (PMID: 31158244). | 31158244 |
PubMed Id | Reference Title | Details |
---|---|---|
(31158244) | Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. | Full reference... |